Long-term and low-dose rituximab treatment for chronic inflammatory demyelinating polyneuropathy

IF 3.9 3区医学 Q1 CLINICAL NEUROLOGY

Journal of the Peripheral Nervous System Pub Date : 2024-08-17 DOI:10.1111/jns.12653

Yongsheng Zheng, Chong Sun, Yanyin Zhao, Quanhua Meng, Jianian Hu, Kai Qiao, Jian Sun, Jianying Xi, Sushan Luo, Jiahong Lu, Chongbo Zhao, Jie Lin

{"title":"Long-term and low-dose rituximab treatment for chronic inflammatory demyelinating polyneuropathy","authors":"Yongsheng Zheng, Chong Sun, Yanyin Zhao, Quanhua Meng, Jianian Hu, Kai Qiao, Jian Sun, Jianying Xi, Sushan Luo, Jiahong Lu, Chongbo Zhao, Jie Lin","doi":"10.1111/jns.12653","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Objective</h3>\n \n <p>To evaluate the efficacy and safety of a low-dose, long-term rituximab regimen in the treatment of idiopathic CIDP.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>This study included 15 CIDP patients treated with rituximab. Patients were administered 600 mg of rituximab intravenously every 6 months. Baseline evaluation was conducted before the initiation of rituximab treatment and subsequent evaluations were conducted 6 months after each rituximab infusion at on-site visits. Clinical improvement was objectively determined by improvement of scale score at least decrease ≥1 INCAT or mRS or increase ≥4 MRC or ≥8 cI-RODS after each infusion compared to baseline evaluation.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Fifteen CIDP patients were included and 10 of them were typical CIDP and five were distal CIDP. Nine in 15 (60%) patients after first infusion and three in six (50%) patients after second infusion exhibited significant clinical improvement compared to baseline evaluation. Additionally, rituximab facilitated a reduction or cessation of other medications in 73% of patients at last visit. The safety profile was favorable, with no reported adverse events.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>Rituximab presents a promising therapeutic option for idiopathic CIDP, offering both efficacy and safety with a low-dose, long-term regimen.</p>\n </section>\n </div>","PeriodicalId":17451,"journal":{"name":"Journal of the Peripheral Nervous System","volume":"29 3","pages":"350-355"},"PeriodicalIF":3.9000,"publicationDate":"2024-08-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the Peripheral Nervous System","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/jns.12653","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective

To evaluate the efficacy and safety of a low-dose, long-term rituximab regimen in the treatment of idiopathic CIDP.

Methods

This study included 15 CIDP patients treated with rituximab. Patients were administered 600 mg of rituximab intravenously every 6 months. Baseline evaluation was conducted before the initiation of rituximab treatment and subsequent evaluations were conducted 6 months after each rituximab infusion at on-site visits. Clinical improvement was objectively determined by improvement of scale score at least decrease ≥1 INCAT or mRS or increase ≥4 MRC or ≥8 cI-RODS after each infusion compared to baseline evaluation.

Results

Fifteen CIDP patients were included and 10 of them were typical CIDP and five were distal CIDP. Nine in 15 (60%) patients after first infusion and three in six (50%) patients after second infusion exhibited significant clinical improvement compared to baseline evaluation. Additionally, rituximab facilitated a reduction or cessation of other medications in 73% of patients at last visit. The safety profile was favorable, with no reported adverse events.

Conclusion

Rituximab presents a promising therapeutic option for idiopathic CIDP, offering both efficacy and safety with a low-dose, long-term regimen.

查看原文本刊更多论文

慢性炎症性脱髓鞘性多发性神经病的长期和低剂量利妥昔单抗治疗。

目的：评估低剂量、长期利妥昔单抗治疗特发性CIDP的疗效和安全性：评估低剂量、长期利妥昔单抗方案治疗特发性 CIDP 的有效性和安全性：本研究纳入了15名接受利妥昔单抗治疗的CIDP患者。患者每 6 个月静脉注射 600 毫克利妥昔单抗。在开始利妥昔单抗治疗前进行基线评估，每次输注利妥昔单抗 6 个月后进行现场评估。与基线评估相比，每次输注后的量表评分至少下降≥1 INCAT或mRS，或上升≥4 MRC或≥8 cI-RODS，以此客观判定临床改善情况：共纳入15例CIDP患者，其中10例为典型CIDP，5例为远端CIDP。与基线评估结果相比，15 名患者中有 9 人（60%）在第一次输液后临床症状明显改善，6 名患者中有 3 人（50%）在第二次输液后临床症状明显改善。此外，利妥昔单抗还有助于73%的患者在最后一次就诊时减少或停用其他药物。安全性状况良好，无不良反应报告：利妥昔单抗为特发性CIDP提供了一种前景广阔的治疗方案，它以低剂量、长期方案提供了疗效和安全性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of the Peripheral Nervous System 医学-临床神经学

CiteScore

6.10

自引率

7.90%

发文量

审稿时长

>12 weeks

期刊介绍： The Journal of the Peripheral Nervous System is the official journal of the Peripheral Nerve Society. Founded in 1996, it is the scientific journal of choice for clinicians, clinical scientists and basic neuroscientists interested in all aspects of biology and clinical research of peripheral nervous system disorders. The Journal of the Peripheral Nervous System is a peer-reviewed journal that publishes high quality articles on cell and molecular biology, genomics, neuropathic pain, clinical research, trials, and unique case reports on inherited and acquired peripheral neuropathies. Original articles are organized according to the topic in one of four specific areas: Mechanisms of Disease, Genetics, Clinical Research, and Clinical Trials. The journal also publishes regular review papers on hot topics and Special Issues on basic, clinical, or assembled research in the field of peripheral nervous system disorders. Authors interested in contributing a review-type article or a Special Issue should contact the Editorial Office to discuss the scope of the proposed article with the Editor-in-Chief.